Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 13/20 | 1.00 |
| ▸ | DRD3 | P35462 | 13/20 | 1.00 |
| ▸ | HTR1A | P08908 | 3/20 | 0.55 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | DRD4 | P21917 | 1/20 | 0.35 |
| ▸ | PARP1 | P09874 | 1/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fumaric Acid SCHEMBL2965270 | 0.89 | DRD2 (0.79) | DRD2DRD3HTR1A | |
| SCHEMBL6356040 | 0.82 | DRD2 (0.70) | DRD2DRD3HTR1ADRD4SIGMAR1 | |
| SCHEMBL7344010 | 0.79 | DRD2 (0.65) | DRD2DRD3HTR1A | |
| SCHEMBL7376178 | 0.77 | DRD2 (0.62) | DRD2DRD3HTR1ASLC6A2SLC6A4 | |
| SCHEMBL7343813 | 0.77 | DRD2 (1.00) | DRD2DRD3HTR1ASLC6A2SLC6A4 | |
| SCHEMBL3222580 | 0.77 | DRD2 (1.00) | DRD2DRD3HTR1ASLC6A2SLC6A4 | |
| Hydrochloric Acid SCHEMBL7343645 | 0.76 | DRD2 (0.61) | DRD2DRD3HTR1ASLC6A2SLC6A4 | |
| SCHEMBL7348495 | 0.73 | DRD2 (0.58) | DRD2DRD3HTR1APARP1 | |
| SCHEMBL23261645 | 0.73 | DRD2 (0.57) | DRD2DRD3HTR1ASLC6A2SLC6A4 | |
| SCHEMBL31649518 | 0.73 | DRD2 (0.57) | DRD2DRD3HTR1ASLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050107378-A1 | Heterocyclic amines having central nervous system activity | ROMERO ARTHUR G (US) | 2005-05-19 | — | — | US | disclosed |
| WO-2004108120-A1 | USE OF GROWTH HORMONE SECRETAGOGUES FOR TREATMENT OF FIBROMYALGIA | PFIZER PRODUCTS INC. (US) | 2004-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107378-A1 | Heterocyclic amines having central nervous system activity | CNR1, CNR2, NPY2R | DRD2 59/4885DRD3 48/4885HTR1A 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.